brexucabtagene autoleucel at a glance
Medicine class
CD19-directed autologous CAR T-cell immunotherapy
Licensed uses
Selected adults with relapsed or refractory mantle cell lymphoma or B-cell precursor acute lymphoblastic leukaemia
Administration
A patient-specific intravenous infusion given at a qualified treatment centre
Important monitoring
Close monitoring for cytokine release syndrome, neurological effects, infection and low blood counts
What is brexucabtagene autoleucel used for?
UK-licensed uses are:
Adults with relapsed or refractory mantle cell lymphoma after at least two previous systemic treatment lines, including a Bruton's tyrosine kinase inhibitor.
Adults aged 26 years or older with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia.
How does brexucabtagene autoleucel work?
The patient’s T cells are genetically modified to carry a receptor that binds CD19. Contact with a CD19-expressing cancer cell activates and expands these cells so they kill the target cell. Normal CD19-positive B cells can also be affected, potentially reducing antibody levels and increasing infection risk.
How to take brexucabtagene autoleucel
This treatment is not taken at home. The specialist centre collects the patient’s white blood cells, arranges manufacture of the patient-specific product and administers it intravenously after preparatory treatment.
Confirm identity carefully because the infusion bag is made for one named patient only.
Administration and early monitoring take place in a qualified specialist centre with emergency treatment available.
Remain near the treatment centre and follow its monitoring and contact instructions after discharge.
Carry the patient alert card and show it to healthcare professionals involved in your care.
brexucabtagene autoleucel side effects
Common or expected effects
- Cytokine release syndrome, often involving fever, chills, low blood pressure, fast heartbeat or breathing difficulty
- Infections and fever associated with low white-cell counts
- Low red cells, white cells or platelets
- Confusion, headache, tremor, speech difficulty, dizziness or other neurological effects
- Fatigue, reduced appetite and muscle or joint pain
- Nausea, vomiting, diarrhoea, constipation or abdominal pain
- Cough, breathlessness or low oxygen levels
- Reduced immunoglobulin levels
Get urgent medical advice
- Severe cytokine release syndrome, particularly high fever with low blood pressure, low oxygen or organ dysfunction
- Neurological toxicity, including confusion, inability to speak, severe drowsiness, seizure or reduced consciousness
- Serious infection or febrile neutropenia
- Severe allergic reaction, including anaphylaxis
- Tumour lysis syndrome, which can impair kidney function and disturb blood salts
- Severe or prolonged low blood-cell counts with bleeding or infection
- New malignancy after CAR T-cell treatment
brexucabtagene autoleucel in pregnancy
There are no adequate pregnancy data. Harm to the fetus cannot be excluded because the modified cells could affect fetal B cells. Treatment is not recommended during pregnancy or where contraception is not being used. Pregnancy status is checked beforehand; discuss any pregnancy after treatment promptly with the specialist team.
brexucabtagene autoleucel while breastfeeding
It is unknown whether the modified cells can pass into breast milk or affect a breastfed child. Discuss feeding options with the specialist team because a potential risk cannot be excluded.
brexucabtagene autoleucel interactions
Formal interaction studies have not been performed. Important considerations include:
Systemic corticosteroids
Preventive use before infusion may interfere with CAR T-cell activity. Specialists may still use corticosteroids to manage treatment-related toxicity.
Live viral vaccines
Avoid before preparatory chemotherapy, during treatment and until immune recovery because safety has not been established.
Common questions about brexucabtagene autoleucel
Answers are fully visible for fast scanning and source review.
What is brexucabtagene autoleucel?
A personalised CAR T-cell gene therapy made from a patient’s own T cells and designed to target CD19-positive B cells.
Where is it given?
It is administered intravenously in a qualified specialist centre equipped to manage CAR T-cell complications.
Why must I stay near the hospital?
Cytokine release syndrome and neurological toxicity can develop after treatment, so rapid specialist assessment must remain available.
Can I drive after treatment?
Do not drive or operate dangerous machinery for at least eight weeks after infusion, or longer if neurological effects have not resolved.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.